Latest Commercialization News

Kinetiko Energy has secured approval to trade on the North American OTCQB Market, aiming to boost investor access and liquidity as it advances its South African gas projects.

Carnegie Clean Energy’s Spanish subsidiary has sold its 2025 Basque R&D tax deductions for €773,163, securing immediate funding to advance its ocean wave energy technology under the ACHIEVE Programme.

BCI Minerals has secured crucial environmental approvals to proceed with its optimized dredging strategy at the Mardie Salt Operation, setting the stage for first salt shipments by late 2026.

Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.

AusQuest Limited’s recent reconnaissance drilling at its Mt Davis Project in Western Australia has revealed promising lead, copper, and silver anomalies, suggesting potential for sediment-hosted base metal deposits.

Capricorn Metals has secured the Yalgoo Project, significantly enlarging its Mt Gibson Gold Project tenure and setting the stage for new exploration in 2026.

Tempest Minerals has agreed to sell its Yalgoo Project to Capricorn Metals for $4.5 million in cash and shares, with additional payments tied to future discoveries and production milestones. The deal, expected to complete in early 2026, leaves Tempest retaining iron rights on key tenements while refocusing on other Western Australian assets.

Adisyn Ltd has completed a strategic review, deciding to boost investment in its graphene-based semiconductor arm while exploring options to unlock value from its managed IT services business.

Cavalier Resources has signed a landmark Native Title Agreement with the Wangkatja Aboriginal Corporation, clearing a major hurdle for the Crawford Gold Project. Alongside this, an updated Pre-Feasibility Study confirms robust economics underpinning near-term production.

Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.

Blue Star Helium has successfully started helium production at its Galactica project in Colorado, positioning itself as America’s newest helium producer with sales targeted for early 2026. The company’s strategic joint venture and low-cost operations underpin a promising growth trajectory amid rising helium and CO₂ demand.

CONNEQT Health has raised $3.1 million through an institutional placement to fuel growth of its Pulse vascular health device, supported by both new and existing investors including its largest shareholder.